Please login to the form below

Not currently logged in
Email:
Password:

Eperzan

This page shows the latest Eperzan news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk's oral GLP-1 analogue looks set for phase III

Novo Nordisk's oral GLP-1 analogue looks set for phase III

If the injectable version is approved it will have to compete with a number of similar products on the market - notably AstraZeneca's Bydureon (exenatide), GlaxoSmithKline's Tanzeum/Eperzan (albiglutide) and

Latest news

  • FDA approves Lilly’s GLP-1 diabetes drug Trulicity FDA approves Lilly’s GLP-1 diabetes drug Trulicity

    Competition is heating up, however, and GlaxoSmithKline has won approval for once-weekly albiglutide in the US under the name Tanzeum and in the EU under the name Eperzan.

  • GSK gets OK in US for diabetes drug albiglutide GSK gets OK in US for diabetes drug albiglutide

    Albiglutide - which will be sold in Europe as Eperzan - has been approved for improving glycaemic control along with diet and exercise, and can be used alone or in combination with other

  • EMA clears GSK's diabetes therapy Eperzan EMA clears GSK's diabetes therapy Eperzan

    EMA clears GSK's diabetes therapy Eperzan. Once-weekly GLP-1 therapy will line-up against Victoza and Byetta. ... GlaxoSmithKline says it will launch its once-weekly diabetes therapy Eperzan in the EU later this year after winning approval for the GLP-1

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    GlaxoSmithKline's (GSK) new diabetes drug Eperzan was among four new pharma products recommended for approval at the end of last week by the European Medicines Agency (EMA). ... Eperzan (albiglutide) stood out among the recommendations as it is GSK's

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    GSK submits albiglutide for European approval. If approved the diabetes drug will be launched as Eperzan. ... If approved the biologic treatment, which was submitted for US approval in January, will be marketed as Eperzan.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics